UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000008191
Receipt number R000009653
Scientific Title Examination for the effect of combination therapy with Eldecalcitol and Alendronate in primary osteoporotic patients
Date of disclosure of the study information 2012/06/18
Last modified on 2017/12/23 11:54:47

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Examination for the effect of combination therapy with Eldecalcitol and Alendronate in primary osteoporotic patients

Acronym

Examination for the effect of combination therapy with Eldecalcitol and Alendronate in primary osteoporotic patients

Scientific Title

Examination for the effect of combination therapy with Eldecalcitol and Alendronate in primary osteoporotic patients

Scientific Title:Acronym

Examination for the effect of combination therapy with Eldecalcitol and Alendronate in primary osteoporotic patients

Region

Japan


Condition

Condition

Osteoporosis

Classification by specialty

Endocrinology and Metabolism Orthopedics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the effect and safety in primary osteoporotic patients undergoing therapy with Alendronate by adding Eldecalcitol

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Phase IV


Assessment

Primary outcomes

Change of lumbar spine bone mineral density

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

YES

Concealment

Numbered container method


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Alendronate (35mg/week) + Eldecalcitol (0.75ug/day) for 48 weeks

Interventions/Control_2

Alendronate (35mg/week)

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Primary osteoporotic patients
2.Patients who are treated with Alendronate for more than two years
3.Patients with informed of consent

Key exclusion criteria

1. Patients who are diagnosed as contraindication of Alendronate treatments
2. Patients who are diagnosed as contraindication of Eldecalcitol treatments
3.Patients who have taken osteoporosis treatments other than Alendronate
4.Patients with cancer
5. Patients who are inappropriate for this study by physician

Target sample size

100


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Takashi Nagai

Organization

Showa University

Division name

Department of Orthopaedic Surgery

Zip code


Address

1-5-18 Hatanodai, Shinagawa-ku, Tokyo, Japan

TEL

03-3784-8543

Email

nagai.babby@gmail.com


Public contact

Name of contact person

1st name
Middle name
Last name Takashi Nagai

Organization

Showa University

Division name

Department of Orthopaedic Surgery

Zip code


Address

1-5-18 Hatanodai, Shinagawa-ku, Tokyo, Japan

TEL

03-3784-8543

Homepage URL


Email

nagai.babby@gmail.com


Sponsor or person

Institute

Showa University

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

昭和大学病院(東京都)


Other administrative information

Date of disclosure of the study information

2012 Year 06 Month 18 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2011 Year 11 Month 16 Day

Date of IRB


Anticipated trial start date

2012 Year 06 Month 01 Day

Last follow-up date

2017 Year 11 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2012 Year 06 Month 18 Day

Last modified on

2017 Year 12 Month 23 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009653


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name